Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium Nitrite in COVID-19 lung injury
NCT04401527Phase 2Withdrawn
- Sponsor
- Hope Pharmaceuticals
- Start
- Jul 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sodium nitrite in coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS) and not applicable; "lung injury" is not a specific disease, sponsored by Hope Pharmaceuticals. Primary endpoint: Survival with Unassisted Breathing at Day 28. Planned start Jul 2020; status: withdrawn.
02
Drugs
sodium nitrite
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)not applicable; "lung injury" is not a specific disease
Beyond the preview
Go deeper on NCT04401527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04401527.